NVCT - NASDAQ

Nuvectis Pharma, Inc.

NVCT·NASDAQ

$9.42

-0.95%

HealthcareBiotechnology

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$249.87M

EPS-1.3200

P/E Ratio-7.14

Earnings Date08/04/2026

nvct

Cash at Beginning of Period

Last Annual Value

18.53M

3-Year CAGR

48%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Nuvectis Pharma, Inc. Competitors Analysis of Cash at Beginning of Period

NVCT · NASDAQ

Company	Cash at Beginning of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
Nuvectis Pharma, Inc. NASDAQ:NVCT	18.53M	-2.5%	N/A	N/A
Alto Neuroscience, Inc. NYSE:ANRO	168.73M	51.7%	111.3%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	58.94M	21.3%	-20.4%	N/A
PepGen Inc. NASDAQ:PEPG	50.97M	-34.7%	39.1%	N/A
Actuate Therapeutics Inc NASDAQ:ACTU	8.64M	-25.0%	N/A	N/A
Atossa Therapeutics, Inc. NASDAQ:ATOS	71.19M	-13.8%	12.4%	34.4%
Greenwich LifeSciences, Inc. NASDAQ:GLSI	4.09M	-32.8%	-32.2%	N/A
Tevogen Bio Holdings Inc. NASDAQ:TVGN	1.05M	-42.3%	207.3%	N/A
Cardiff Oncology, Inc. NASDAQ:CRDF	51.47M	46.6%	-17.0%	-2.7%
Rani Therapeutics Holdings, Inc. NASDAQ:RANI	4.26M	-46.3%	-43.4%	N/A
Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP	99.68M	-6.1%	5.2%	17.9%

Nuvectis Pharma, Inc. Fair Value Envelope

NVCT · NASDAQ

Our analysis suggests that NVCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.42, this represents a potential HIDDEN relative to our calculated worth for Nuvectis Pharma, Inc..

HIDDEN

Intrinsic Value

Current Price: $9.42

Related Guides

Blog Categories

Continue your NVCT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.